Home

Geneva, 2 February 2010

As BioSquare 2010 winds down this evening I am filled with gratitude towards all the sponsors, partners and participants who made this our most successful BioSquare ever. Deals were made, contacts were countless and the venue was extremely well received. As you can imagine, we are not stopping here. BioSquare 2011 will dare go further which is why we invite you to visit our website in early March for some outstanding news. Finally, I would also like to thank our staff and service partners who gave me incredible support.

In closing, I wish you continued business development throughout 2010.

Warm regards,

Bernadette Guagliata, CEO

Redefining Healthcare through Bioconvergence

G. Steven Burrill

"The dizzing pace of innovation promises to redefine healthcare. The combination of biotechnology with nanotechnology, medtechnology and information technology will transform the way doctors monitor, diagnose and treat disease.

BioSquare is totally part of this deep and global transformation of the sector: the conference is a two-day event which aims at bringing together stakeholders from across the value chain of these innovative technologies convergence. BioSquare 2010 will concentrate time and expertise for theses companies looking for partnerships in one of the world’s key financial place.”

G. Steven Burrill, CEO Burrill & Company

Patrick Aebischer, G. Steven Burrill, Pierre Hessler, Elmar Schnee, Paul Stoffels and Christopher A. Viehbacher to deliver Opening Keynote address

BioSquare Keynote Event: Monday February 1st, 2010 at 11:15 am

Patrick Aebischer

President, Ecole Polytechnique de Lausanne

G. Steven Burrill,

CEO, Burrill & Company

Pierre Hessler

Member of the Directoire, Capgemini Service SAS

Elmar Schnee,

President, Merck Serono

Paul Stoffels,

Global Head, R&D, Pharmaceuticals Johnson & Johnson

Christopher A. Viehbacher,

CEO, Sanofi-aventis

Welcome

Just a quick word to tell you how thrilled I am to welcome you to BioSquare 2010…

Indeed, despite the ’08-09’ economic crisis, the BioSquare team have chosen to upgrade and refine BioSquare. In no uncertain terms, we pledge this event will mark a paradigm shift in the way PHARMACEUTICAL, BIOTECH PHARMAS, NANOTECH, MEDTECH and IN SILICO companies build partnerships.

I look forward to greeting you personally.

Bernadette Guagliata, CEO

BioSquare V2.0

Fact

Effective partnering opportunities lead to successful ventures.

Fact

Biotech, medtech, nanotech and in silico sectors are coming together as never before; we are witnessing the birth of bioconvergence.

Fact

The new BioSquare is the premiere bioconvergence partnering meeting for mature companies, high potential start-ups or willing investors working in the bioconvergence universe worldwide.

Fact

Expect an event that adds to your bottom line.

Did we mention it’s going to be the most enjoyable BioSquare ever?

BioSquare V2.0 Highlights

BioSquare has set high goals. It has also retained key fundamentals.

Make valuable business connections

The one-to-one paradigm lives on but with major changes. You will meet people in far more comfort, with greater privacy and with superior presentation options.

New BioSquare partnering software

No modern partnering event can function without a one-to-one partnering platform. A superior event needs a flawless application that is easy to use and flexible. Our goal is to continue software development year to year; we consider keeping our partnering application current an essential task. Those who use the application to its fullest extent, prior to, during and after the event will establish high value business connections.

More

Sponsorship opportunities revisited

Sponsorship and visibility opportunities are still on the menu but BioSquare is streamlining them. Visibility has been well studied to maximise impact — we want attendees to see your message, retain your message and act on your message.

More

Presentations

Selected presentations of portfolio strategies have been, and are still, part of the programme with the same heightened obsession to maximise impact. In 2010, BioSquare will place particular emphasis on promising young talents.

More

Panels and Workshops

BioSquare 2010’s conference track is entirely devoted to business development and innovation with few select keynote speeches and exciting speakers challenged by professional moderators.

More

Who should attend?

BioSquare targets decision-makers that are ready to deal.

Historically, 46% of BioSquare attendees are President/CEO/Partner level, 21% are Senior VP/Director level and the remainder is academia, media and middle management. Over the last three BioSquare events the trend has been leaning towards higher-level attendees (President/CEO/Partner).

Camembert animé

Sectorially, those that have regularly attended BioSquare are bio-technology companies, medical-technology companies, nano-technology companies, diagnostics, pharmaceutical, technology licensing offices, major research institutions, high potential start-ups and investment companies and individuals — without planning on it, we were a bioconvergence event all along.

Clearly, all life sciences players are welcome, but our focus is on companies that are sufficiently mature in their development to warrant an imminent investment or partnership.

Back to top